Valeant Pharmaceuticals boosts stock buyback program by $300m
News | 29 August 2011
Drug maker Valeant Pharmaceuticals (TSE:VRX) said Monday its board has approved a $300 million increase in its share buyback program. Mississauga-based Valeant plans to repurchase up to $1.8 billion in senior notes, convertible notes and common shares. ...
Click on the link to read the full article at Proactive Investors USA & Canada
(This link will open in a new window)
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
